Leadership & Pay ·
Stoke Therapeutics announced that Edward M. Kaye resigned as a Class III director and R&D committee member effective…
STOKStoke Therapeutics, Inc.
Stoke Therapeutics announced that Edward M. Kaye resigned as a Class III director and R&D committee member effective September 23, 2026, citing no disagreements with the company. The board appointed Alexander (Bo) Cumbo to fill the vacancy for a term expiring at the 2028 Annual Meeting. Mr. Cumbo received an annual cash retainer of $45,000 and an initial stock option grant valued at approximately $724,000 covering 39,674 shares. Stoke Therapeutics operates in the biotechnology industry, focusing on developing treatments for genetic diseases.